APIM
ENZ

Agate Pass Investment Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Agate Pass Investment Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,292
Closed -$30K – 93
2023
Q2 		$30K Buy
+16,292
New +$37.7K 0.02% 93
2023
Q1 		– Sell
-16,292
Closed -$23.3K – 97
2022
Q4 		$23.3K Buy
+16,292
New +$31.7K 0.02% 94
2022
Q1 		– Sell
-24,292
Closed -$78K – 99
2021
Q4 		$78K Buy
+24,292
New +$82.9K 0.05% 99

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Agate Pass Investment Management's ENZ Position: Q3 2023 in Review

Agate Pass Investment Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2023, closing a stake of 16,292 shares — an estimated $30K sold.

Agate Pass Investment Management first reported a position in ENZ in Q4 2021 and held it in 3 quarters. The position peaked at $78K in Q4 2021. 39 funds tracked by Wall St. Rank hold ENZ as of Q3 2023.

  • Agate Pass Investment Management reported no remaining Enzo Biochem, Inc. position as of Q3 2023 after selling out during the quarter.
  • Agate Pass Investment Management sold 16,292 Enzo Biochem, Inc. shares in Q3 2023, an estimated $30K.
  • Agate Pass Investment Management first reported a position in Enzo Biochem, Inc. in Q4 2021 and held it in 3 quarters.
  • Agate Pass Investment Management's Enzo Biochem, Inc. position peaked at $78K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2023.

Based on Agate Pass Investment Management's 13F filing for Q3 2023, filed 13 Oct 2023.